ArticleInternational journal of clinical and experimental medicine2015
Lack of association between interleukin-2 (IL-2) gene rs2069762 polymorphism and cancer risk: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Are single nucleotide polymorphisms in the IL-2 gene biomarkers for Hashimoto's thyroiditis?Medicine and pharmacy reports · 2024Article
- Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors-Potential Clinical Relevance.Journal of clinical medicine · 2022Article
- Effects of Soy Product Intake and Interleukin Genetic Polymorphisms on Early Gastric Cancer Risk in Korea: A Case-Control Study.Cancer research and treatment · 2017Article
- Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-2 (IL-2) is an important member of the cytokines that play critical roles in carcinogenesis. Many studies have investigated the association between IL-2 rs2069762 polymorphism and cancer risk; however, the results remain controversial. The aim of this study is to assess the correlation between IL-2 rs2069762 polymorphism and cancer risk. All eligible case-control studies accorded with criteria published up to March 30, 2015 were identified by searching Embase and PubMed databases. Association between IL-2 rs2069762 polymorphism and cancer risk was assessed by crude odds ratios (ORs) with 95% confidence intervals (CIs), respectively. Ten case-control studies from nine publications with 3095 cases and 4480 controls were included. Overall, IL-2 rs2069762 polymorphism was not associated with cancer risk in five genetic models (G vs. T: OR = 1.07, 95% CI = 0.95-1.21, P = 0.278; GG vs. TT: OR = 1.16, 95% CI = 0.86-1.57, P = 0.317; GG + TG vs. TT: OR = 1.09, 95% CI = 0.93-1.28, P = 0.273; GG vs. TT + TG: OR = 1.11, 95% CI = 0.85-1.44, P = 0.451; TG vs. TT: OR = 1.08, 95% CI = 0.92-1.28, P = 0.339, respectively). Similar results were also obtained after stratified by ethnicity and cancer type. This meta-analysis indicates that IL-2 rs2069762 T>G polymorphism is not associated with cancer risk. And the same conclusion is drawn after stratified by cancer type and ethnicity.
Indexed as
Identifiers
26550166PMC4612851W2194416568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.